MedTrace Logo

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

NCT00843531 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2020-09-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test how safe and effective the combination of RAD001 and erlotinib is in patients with neuroendocrine tumors.

Conditions

Interventions

DRUG

RAD001

5 mg/day PO (oral)

DRUG

erlotinib

100 mg/day (oral)

Sponsors & Collaborators

Principal Investigators

  • Emily K. Bergsland, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-25
Primary Completion
2013-07-16
Completion
2016-08-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00843531 on ClinicalTrials.gov